Qiagen reported mixed Q1 results. Double-digit growth in the non-COVID-19 product group was, however, offset by the significant decline in COVID-19 sales. Notably, 2023 guidance was maintained, suggesting healthy dynamics for its non-COVID-19 product portfolio. Overall, considering non-COVID-19 testing tailwinds will continue along with the firm’s healthy measures in expanding the scope of offerings and bolt-on initiatives, our positive stock recommendation is maintained.